Expansion of adult stem cells in vitro
Disclosed are methods for manipulating and expanding stem cell populations, including adult stem cells, the cells produced by such methods, and various protein constructs related thereto.
1. A method for producing a population of conditionally immortalized adult stem cells comprising:
a) contacting one or more adult stem cells with
i) an exogenously synthesized Myc-fusion polypeptide that promotes one or more of cell survival or proliferation, wherein the Myc-fusion polypeptide comprises a Myc polypeptide fused to a protein transduction domain; and
ii) an exogenously synthesized Bcl-2 domain polypeptide that inhibits apoptosis; and
b) seeding the adult stem cells in a culture vessel so as to produce a population of conditionally immortalized adult stem cells,
wherein adult stem cells are contacted with the Myc-fusion polypeptide and the Bcl-2 domain polypeptide prior to seeding and wherein the Myc-fusion polypeptide and the Bcl-2 domain polypeptide are cultured with the cells in the culture vessel for at least 24 hours.
2. The method of claim 1 , wherein the Myc-fusion polypeptide is provided at intervals at least 72 hours; and the Bcl-2 domain polypeptide is at intervals of at least 72 hours.
3. The method of claim 1 , wherein the Myc polypeptide of the Myc-fusion polypeptide is one or more of n-Myc, c-Myc, 1-Myc, v-Myc, or s-Myc.
4. The method of claim 1 , wherein the Myc-fusion polypeptide is provided at a concentration of about 1 ug/ml to about 50 ug/ml.
5. The method of claim 1 , wherein the Bcl-2 domain polypeptide is provided at a concentration of about 1 ug/ml to about 50 ug/ml.
6. The method of claim 1 , wherein the Bcl-2 domain polypeptide includes BH1, BH2, BH3, and BH4.
7. The method of claim 1 , wherein the one or more Bcl-2 domain polypeptide is one or more of Bcl-2, Bcl-w, Bcl-X, Bel-XL, Mcl-1.
8. The method of claim 1 , wherein the one or more Bcl-2 domain polypeptide is Bcl-2.
9. The method of claim 1 , wherein the Bcl-2 polypeptide includes a protein transduction domain selected from the group consisting of Tat, EPTD and vpr.
10. The method of claim 9 , wherein the protein transduction domain is Tat.
11. The method of claim 9 , wherein the protein transduction domain is EPTD.
12. The method of claim 9 , wherein the protein transduction domain is vpr.
13. The method of claim 1 , wherein the one or more adult stem cells are cultured in media comprising IL3, IL6, and stem cell factor.
14. The method of claim 1 , wherein the one or more adult stem cells are cultured in media comprising IL3, IL6, stem cell factor, thrombopoietin, and Flt3-L, and GM-CSF.
15. The method of claim 1 , wherein the one or more adult stem cells are expanded one or more of about 270 fold over about 28 days, about 150 fold over about 14 days, 100 fold over about 21 days, or about 85 fold over about 9 to 14 days.
16. The method of claim 1 , wherein the one or more adult stem cells are one or more hematopoietic adult stem cells.
17. The method of claim 16 , wherein the hematopoietic adult stem cells are human cord blood-derived hematopoietic stem cells, human G-CSF mobilized peripheral blood hematopoietic stem cells, or human bone marrow hematopoietic stem cells.
18. The method of claim 1 , wherein, over a 8 hour period, no more than 1 μg/ml of Myc-fusion polypeptide is provided.
19. The method of claim 1 , wherein the Myc-fusion polypeptide is provided at intervals at least 96 hours; and the Bcl-2 domain polypeptide is at intervals of at least 96 hours.
20. The method of claim 1 , wherein the Myc-fusion polypeptide is provided at intervals at least 48 hours; and the Bcl-2 domain polypeptide is at intervals of at least 48 hours.